Author: Dr. David Lowemann

Animals and the iterative natural kind strategy

What entities are conscious and how could we ever know? We recently provided a framework for developing validated tests for consciousness (‘C-tests’): the Iterative Natural Kind Strategy (INKS) [1]. Brown and colleagues [2] raise some important questions for the INKS approach, although we are not sure how different their answers to those questions are from […]

Published on August 23, 2024

To test the boundaries of consciousness, study animals

How can we validate tests for consciousness beyond healthy adult humans? Bayne and colleagues propose the ‘iterative natural kind strategy’ (INKS) [1]. INKS begins by taking seriously all tests with at least some face validity rather than restricting our attention to a small subset of tests that antecedently pass stringent requirements of validation. We then […]

Published on August 23, 2024

New Cancer Drugs May Also Slow Alzheimer’s Disease

A new type of cancer drug might help treat brain diseases like Alzheimer’s, mouse studies suggest. The drugs block an enzyme called indoleamine-2,3-dioxygenase 1 (IDO1), researchers reported. IDO1 inhibitors are being developed as a treatment for cancers like melanoma,… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of […]

Published on August 23, 2024